Loading
Latest filing published 29 Dec 2025 for Remus Pharmaceuticals Limited, €8,341.
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Arpit Deepakkumar Shah, listed as major shareholder, appears in our data through filings on Remus Pharmaceuticals Limited shares, published by SEBI (PIT + SAST). In total, 57 filings cover trades dated from 21 September 2023 to 19 December 2025.
Every open-market trade on record is a purchase: 57 purchases worth €651k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2025 alone, the filings show 1 purchase and no sales.
In size, the median ticket on the buying side is €5,368. On 57 out of 57 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
The record was last updated on 29 December 2025 with an open-market purchase (€8,341) in Remus Pharmaceuticals Limited. Filings reach the SEBI (PIT + SAST) feed a median of 1 day after the trade. This delay matters because a trade only becomes useful information once it is public. Source: insider filings from SEBI (PIT + SAST). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 57 declarations